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Efficacy of local inhibition of procoagulant 
activity associated with small-diameter 
prosthetic vascular grafts 
Luigi Oltrona, MD,  Patti R. Eisenberg, MD,  MPH,  Dana R. Abendschein, PhD,  and 
Brian G. Rubin,  MD,  St. Louis, Mo. 
Purpose: Graft procoagulant activity is determined by thrombin (IIa) and activated factor 
X (Xa) that binds to thrombus. Thrombus-associated factor Xa and thrombin are resistant 
to antithrombin III-dependent therapy (heparin). To avoid complications and costs 
associated with systemic administration, we evaluated whether locally applied antithrom- 
boric agents inhibit prosthetic graft procoagulant activity under no-flow and low-flow 
conditions. 
Methods: Four-millimeter-diameter collagen-coated grafts were preclotted in recalcified 
human plasma, washed, immersed inantithromboric agents (either 100 um hirudin, 20 ~tm 
D-Phe-L-Pro-L-Arg chloromethylketone, 5 gtm tick anticoagulant peptide or 5 or 10 
p,g/ml tissue factor pathway inhibitor) or saline solution, and extensively rewashed. Grafts 
were exposed to recalcified plasma either in multiwell plates or underwent perfusion at 
1 ml/min flow rate. Fibrinopeptide A, which reflects fibrin elaboration, was measured as 
a marker of thrombin activity. 
Results: Inhibitors reduced flbrinopepride generation at 8 minutes by 55% (tissue factor 
pathway inhibitor), 57% (hirudin), or 63% (tick anticoagulant peptide and D-Phe-L-Pro- 
L-Argchloromethylketone ) compared with the control agents ( p < 0.05). Under low- flow 
conditions tissue factor pathway inhibitor and hirudin reduced fibrinopeptide generation 
at 13 minutes by 61% and 49%, respectively, when compared with control agents 
(p < 0.05). 
Conclusions: Graft-associated inhibitors targeted at factors IIa, Xa, or tissue 
factor/VI Ia/Xa complex effectively reduce procoagulant activity on prosthetic grafts. The 
success of local application of antithrombotic agents in attenuating early fibrin formation 
suggests that this strategy could favorably influence acute graft patency, and we speculate 
these agents may improve long-term graft patency as well. (J Vasc Surg 1996;24:624-31.) 
Small-diameter prosthetic grafts undergo early 
thrombotic occlusion limiting their clinical utility for 
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coronary or peripheral revascularization procedures. 
Thrombin activity has bcen demonstrated on the 
implanted graft 1 and appcars to play a central role in 
graft thrombogenesis. Andthrombin II I- indepen- 
dent thrombin inhibitors reduce thrombus formation 
on vascular grafts in subhuman primates. 2 In contrast, 
the therapeutic efficacy of antithrombin I I I -depen- 
dent thrombin inhibitors (e.g., heparin) has been 
qucstioned. Several clinical reports 3,4 have demon- 
strated that thrombus generation is resistant to con- 
ventional antithrombotic therapy. These findings are 
supported by experimental studies, which show that 
the procoagulant activity ofa thrombus is determined 
by thrombin s-7 and by its precursor in the coagulation 
cascade, activatcd factor X (Xa).S Clot-bound throm- 
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bin retains its biologic activity as a serine protease and 
is capable of inducing fibrin formation but is resistant 
to antithrombin III-mediatcd inhibition. 7 Several 
different antithrombotic agents have been evaluated 
experimentally including (1) direct hrombin inhibi- 
tors like recombinant desulfatohirudin (hirudin) and 
D-Phe-L-Pro-L-Arg chloromethylketone (PPACK), 
(2) specific inhibitors of factor Xa such as recombinant 
tick anticoagulant peptide (TAP), or (3) recombinant 
tissue factor pathway inhibitor (TFPI), which inhibits 
free factor Xa and the tissue factor-VIIa-Xa complex. 
Each of these antithrombotic agents inhibits throm- 
bus-mediated procoagulant activity better than hep- 
arin. 7-9 To measure thrombin activity most studies 
have measured levels of fibrinopeptide A (FPA), a 
cleavage product of the conversion of fibrinogen to 
fibrin. 
Unfortunately, systemic administration of effec- 
tive levels of antithrombotic drugs is expensive and 
may be associated with serious hemorrhagic compli- 
cations. An alternative approach is to immobilize an 
antithrombotic agent at the graft site. This strategy 
offers the advantage of inhibiting the thrombotic 
process at a specific site while avoiding systemic side 
effects. This study was designed to evaluate whether 
initial inhibition of graft-associated thrombin or fac- 
tor Xa on preclotted prosthetic grafts results in 
inhibition of graft-associated procoagulant activity. 
MATERIAL AND METHODS 
Materials. Initial experiments with plasma-clot- 
ted standard (unsealed) Dacron grafts (Meadox 
Medicais Inc, Oakland, N.J.) resulted in leakage of 
plasma through the graft walls during perfusion 
experiments. Therefore l ss porous, collagen-impreg- 
nated 4-mm diameter, Hemashield Microvel double 
velour Dacron (polyester) vascular grafts were se- 
lected and used for all experiments. Silicone tubing 
was purchased from Technical Products, Inc. (Deca- 
tur, Ga.). Citrated plasma was obtained from the 
American Red Cross (St. Louis). Thrombin was 
prepared from purified human prothrombin by acti- 
vation with Taipan snake venom and isolated by 
cation exchange chromatography. The thrombin pre- 
pared contained more than 90% a-thrombin as deter- 
mined by migration on reduced and nonreduced 
sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (SDS-PAGE) and staining by Coomassie 
blue. 12sI flbrinogen was prepared by the lactoperoxi- 
dase method with the use ofEnzymobeads (Bio-rad, 
Hercules, Calif.) according to the manufacturer's 
instructions. PPACK was purchased from Calbio- 
chem (La Jolla, Calif.). Recombinant hirudin was 
obtained from Sigma Chemical Co. (St. Louis). 
Recombinant TAP was provided by Merck Sharp and 
Dohme (West Point, Pa.). Recombinant TFPI was 
provided by Monsanto (St. Louis). 
Preparation of nonclotted grafts. Segments of 
Hemashield graft 5 cm long were immersed in 4 ml 
phosphate-buffered saline solution (PBS) and incu- 
bated at room temperature for 30 minutes (Fig. 1). 
Preparation of plasma dotted grafts. Segments 
of Hemashield graft 5 cm long were immersed in4 ml 
citrated plasma with addition of CaCI 2 and thrombin 
at final concentrations of 25 rnmol/L and 1U/ml, 
respectively, and were incubated at room temperature 
for 30 minutes. The levels of FPA were previously 
determined to be less than 15 ng/ml in the citrated 
plasma used. The grafts were prepared by flushing the 
lumen with a pipette containing PBS and scraping the 
external wall with forceps to remove all visible external 
and intraluminal c ot (Fig. 1). 
Treatment of dotted grafts with antithrom- 
botic agents. Plasma-clotted grafts were immersed in
4 ml PBS containing either 20 ~tm PPACK, 100 ~tm 
hirudin, 5 pm TAP, or 5 or 10 ~tg/ml TFPI and were 
incubated for 30 minutes at room temperature. The 
grafts were extensively rinsed with PBS to remove any 
nonspecifically bound antithrombotic agent. For 
graft incubation experiments the grafts were rinsed by 
immersion in 5 ml. PBS on a vortex shaker for 5 
minutes. This process was repeated four times. For 
graft perfusion experiments he grafts were rinsed 
with normal saline solution at 125 ml/min for 3 
minutes (Fig. 1). 
Graft fibrin deposition experiments. To deter- 
mine the percentage offibrinogen i corporated in the 
wall of the graft with the preclotting procedure, grafts 
were clotted with recalcified plasma containing 
12sI fibrinogen. The amount of 12sI radiolabeled 
fibrin(ogen) retained on the graft after clot formation 
and rinsing was compared with the total amount of 
125I used in clotting the graft. To determine how 
evenly the graft was coated with fibrin(ogen) over its 
length, the graft was cut into 1-cm sections, and the 
125I fibrin(ogen) present on each section was counted. 
Graft incubation experiments. In initial experi- 
ments to characterize the procoagulant activity of 
clotted grafts, nonclotted grafts served as a control 
group. Thrombin activity on clotted and nonclotted 
grafts was measured by incubation of 1-cm segments 
of graft at 25 ° C in pooled citrated plasma repleted 
with CaC12 at a final concentration f 25 mmol/L. 
Aliquots of the plasma were obtained after 3, 5, and 7 
minutes of incubation for measurement of the con- 
centration of FPA. All samples were collected in 
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CLOTTED GRAFT 
PREPARATION 
4mm Hemashleld graft 
Clot grafts at 
25°C for 30 mln in 
citrated plasma, 
25mM CaCI= 
1 U/ml thrombin 
Remove visible 
clot and rinse 
graft with PBS 
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GRAFT 
PREPARATION 
4mm Hemashield graft 
I 
i 
Immerse in 
anticoagulants 
or PBS for 30 rain 
INCUBATION 
EXPERIMENTS 
Vortex in PBS 
for 5 rain X 4 
$ 
Incubate grafts 
in FFP 
$ 
Remove aliquots 
for FPA RIA 
i 
PERFUSION 
EXPERIMENTS 
Rinse graft with 125 
ml/min NS for 3 rain 
$ 
Perfuse grafts with 
FFP at 1 ml/min 
$ 
Collect aliquots 
for FPA RIA 
Hg. 1. Graft preparation. Grafts werc prepared as outlined. Clotted 4-mm Dacron (polyester) 
grafts were rinsed with phosphate-buffered saline solution (PBS), immersed in 4 ml PBS 
containing either 20 I.tm PPACK, 100 gm hirudin, 5 gm TAP, or 5 or 10 gg/ml TFPI, and 
incubated for 30 minutes at room temperature. Nonclotted grafts were rinsed and incubated in
PBS for 30 minutes at room temperature. After extensive washing was performed, grafts 
underwent either incubation or perfusion with pooled fresh-frozen plasma (FFP). 
duplicate into tubes containing 25 gl of a solution 
containing ethylenediamine tetraacetic acid, aproti- 
nin, and PPACK (FPA anticoagulant, Byk-Sangtek) 
and were frozen at -70 ° C. Assays were subsequently 
obtained for FPA. Each experiment was repeated in 
triplicate. 
In subsequent experiments to characterize the 
effects of antithrombotic agents applied locally, 
plasma-clotted grafts not pretreated with antithrom- 
botic agents served as the control group. Segments 
(1 cm) of plasma-clotted grafts with or without 
pretreatment with antithrombotic agents were incu- 
bated in citrated recalcified (25 mmol /L)  plasma in a 
multiwell plate. Aliquots of the plasma were obtained 
at 1-minute intervals for measurement of the concen- 
tration of FPA. Sample collection continued until 
thrombus formation was detected within a well. At 
that time no further samples were obtained, because 
the presence of thrombus made the FPA values 
unreliable. The experiment was continued until all the 
wells contained thrombus. All samples were collected 
in duplicate into tubes containing 25 gl FPA antico- 
agulant and were frozen at -70 ° C. Assays were 
subsequently obtained for FPA. Each experiment was 
repeated in triplicate. 
Graft  perfusion experiments. The procoagulant 
activity of grafts was characterized under flow condi- 
tions with 5-cm lengths of plasma-clotted grafts that 
underwent pcrfusion at the same time in parallel. The 
clotted grafts were pretreated with antithrombotic 
agents, whereas clotted grafts that were untreated 
served as a control group. The grafts underwent 
perfusion with plasma from a syringe pump (Harvard 
Pump 22) connected to the graft by standard intra- 
venous tubing. The middle of  the intravenous tubing 
passed through a37 ° C water bath, but the end of the 
intravenous tubing and the graft were suspended in 
air. The graft underwent perfusion with recaMfied 
plasma at a flow rate of 1 ml/min. New syringes and 
tubing were used for each experiment. The plasma 
was collected ownstream from the graft in 1-minute 
timed aliquots in tubes on ice containing FPA anti- 
coagulant and was frozen at -70 ° C. Assays were 
subsequently obtained for FPA. FPA samples were 
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Fig. 2. Characterization ofprocoagulant activity of plasma clotted grafts compared with that of 
nonclotted grafts. Nonclotted grafts incubated in pooled citrated plasma recalcified with 25 
mmol/L calcium chloride at room temperature resulted in minimal increases in FPA. However, 
increases inFPA were marked when recalcified plasma was incubated with clotted grafts (p < 0.01 
by ANOVA for repeated measures). 
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Fig. 3. Representative examples of two experiments characterizing inhibition of clotted 
graft-associated procoagulant activity after preincubation with specific inhibitors at concentra- 
tions demonstrated to be effective in vivo. A, Preclotted grafts preincubated with PBS (control), 
PPACK (a serine protease inhibitor), or TFPI (an inhibitor of tissue factor/VIIa/Xa complex and 
free factor Xa). B, Preclotted grafts preincubated with PBS (control), hirudin (a thrombin 
inhibitor), or TAP (a Xa inhibitor). At each time interval antithrombotic agent-treated grafts 
generated less FPA than control grafts. 
11 
collected from control and experimental groups until 
thrombus formation was detected within a graft; at 
that time no further samples were collected. The 
experiment was continued until the graft contained 
thrombus. Each experiment was repeated in triplicate. 
Assay for f ibrinopeptide A. Plasma samples were 
absorbed with bentonite before assay was performed 
for FPA to remove fibrinogen and large fibrin degra- 
dation products as previously described, s The con- 
centration of FPA was determined with a polyclonal 
antisera-based commercial radioimmunoassay (Byk- 
Sangtek, Dietzenback, Germany) previously vali- 
dated in our laboratory.a° The lower limit of detection 
is 1 ng/ml,  and the linear range of the assay is 1 to 40 
ng/ml.  Samples containing FPA in excess of 40 
ng/ml  were diluted with pooled plasma with no 
detectable FPA, and assay was performed again. 
Intraassay variability is 5.7% + 0.7%) o 
Recalcified plasma generates thrombin activity in a 
curvilinear fashion over time. An inhibitory effect is 
identified by a delay in the time of onset of the 
exponential rise in FPA generation. Thus the time to 
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Fig. 4. Relative fficacy of preincubation f clotted grafts 
with specific inhibitors for attenuating increases in FPA 
induced after 8 minutes, when grafts were subsequently 
incubated with recalcified citrated plasma under no-flow 
conditions (n = 3 for each condition). Preincubation with 
inhibitors of either thrombin or factor Xa significantly 
attenuated increases inFPA compared with control clotted 
grafts preincubated with PBS (first bar) (*p < 0.05 by 
ANOVA), but no difference was seen between i hibitors. 
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Fig. 5. Representative example of single experiment in 
which clotted grafts were initially preincubated with hiru- 
din, TFPI, or no inhibitor (control), washed, and then 
underwent perfusion at 1 ml/min with recalcified citrated 
plasma. Graft-associated procoagulant activity was charac- 
terized by measuring increases in concentration f FPA. 
Inhibition of either thrombin or Xa with hirudin and TFPI, 
respectively, markedly attenuated increases inFPA induced 
by clotted grafts under these conditions. 
Table I. FPA values after 8 minutes of graft incubation with plasma* 
Control t clotted graft 10 ~tg/ml TFPI 20 ~tM PPA CK 
Experiment (%) (% of control) (% of control) 
1 100 43 24 
2 100 51 63 
3 100 40 23 
Mean + SEM 100 45 + 3~ 37 + 13~ 
% Reduction 0 55 63 
exponential production of FPA rather than maximum 
FPA values reflects attenuated thrombin activity. This 
method of reporting FPA results has become an 
accepted standard for reporting experiments of this 
type and is used in other recent publications on this 
topic. 1° 
Statistical analysis. The data are expressed as the 
mean + SEM. Results were compared with analysis of 
variance for repeated measures. A value of p < 0.05 
was considered significant. Percent of control FPA 
was defined as ([FPA with inhibitor/FPA without 
inhibitor]) × 100, and percent inhibition was defined 
as (1-[FPA with inhibitor/FPA without inhibi- 
tor]) × 100. 
RESULTS 
Graft fibrin deposition experiments. Incuba- 
tion of segments of grafts in recalcified human plasma 
with addition of 12sI-fibrinogen at25 ° C resulted in 
the formation of a plasma clot surrounding and within 
the graft. After mechanical stripping of all visible 
intraluminal and external clot and graft rinsing were 
performed, 1.3% of radiolabeled fibrin(ogen) was 
retained on the graft. Division of the graft into 1-cm 
segments demonstrated 3985 + 305 counts/min of 
retained 12sI-fibrin(ogen) on each segment. 
Graft incubation experiments. Addition of a 
nonclotted graft to recalcified plasma increased FPA 
levels slowly over time, eventually resulting in forma- 
tion of a plasma clot. Plasma-clotted grafts added to 
recaicified plasma-accelerated FPA production mark- 
edly (Fig. 2) and induced more marked increases in 
FPA than observed with the nonclotted graft control 
group by 7 minutes (938 + 90 ng/ml  vs 56 + 45 
ng/ml,  p < 0.01). 
To determine whether anticoagulants modified 
the procoagulant ature of the clotted grafts, clotted 
graft segments were preincubated with selected in- 
hibitors, extensively washed, and exposed to recalci- 
fled plasma. The increases in FPA induced by plasma- 
clotted grafts were significantly attenuated by prein- 
cubafion of grafts in specific antithrombotic agents 
(Fig. 3 and Tables I and II). TFPI-treated grafts 
generated 45% + 3%, PPACK-treated grafts 36% + 
13%, hirudin-treated grafts 43%+ 5%, and TAP- 
treated grafts 37% + 3% of the FPA produced by the 
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control group after 8 minutes (Fig. 4). Thus inhibitor- 
treated grafts ignificantly attenuated increases inFPA 
after 8 minutes by 55% to 63% (p < 0.05) compared 
with clotted graft segments not exposed to inhibitors. 
The 8-minute incubation time point was selected for 
comparisons, because longer incubations often re- 
sulted in plasma clot formation in the control groups. 
Preincubation with thrombin inhibitors was as effec- 
tive as preincubation with factor Xa inhibitors for 
attenuating FPA increases induced by preclotted 
grafts under these conditions. 
Graft perfusion experiments. Under dynamic 
flow conditions plasma-clotted grafts induced marked 
increases in the rate of FPA generation, often with 
plasma thrombus formation within the graft by 10 to 
15 minutes ofperfusion. Because of similar efficacy of 
all the inhibitors tested in the graft incubation experi- 
ments, only hirudin and TFPI were used in the graft 
perfusion experiments o inhibit thrombin or factor 
Xa, respectively. Perfusion with recalcified plasma of 
plasma-clotted grafts treated with 5 gg/ml TFPI or 
100 nm hirudin resulted in attenuation of FPA 
generation compared with the untreated preclotted 
control group (Fig. 5). Grafts treated with TFPI 
resulted in FPA values at 13 minutes of 39% + 9% of 
values in control groups (p < 0.05), and hirudin- 
treated grafts had FPA values of 51% + 8% of control 
groups (p < 0.05) (Table III). The mean reduction in 
FPA production after 13 minutes was 61% by TFPI- 
treated preclotted grafts and 49% by hirudin-treated 
preclotted grafts (Fig. 6). The 13-minute point was 
selected for comparison because ofthrombus forma- 
tion within the control groups with longer perfusion 
times, resulting in unreliable FPA values. 
DISCUSSION 
Immediately after implantation is performed, 
there is protein deposition and activation of the 
coagulation system with adherence of whole blood 
thrombus to the luminal surface of the graft. We 
hypothesized that the progression of thrombosis 
within the graft is dependent on the procoagulant 
activity of the forming thrombus. To characterize the 
procoagulant activity of grafts under these conditions, 
we preclotted prosthetic vascular grafts with plasma. 
We and others have shown that the procoagulant 
activity of plasma clots is determined by the activity of 
thrombin bound to fibrin and of factor Xa associated 
with factor Va on platelet membranes. 8 Others have 
shown that prosthetic grafts implanted as arterio- 
venous fistulas in primates induced thrombin-depen- 
dent, platelet-rich thrombosis, n Because thrombin 
elaboration within grafts is likely to reflect activation 
% of Control 
FPA 
T 
Control 0.1 pM 5 gg/ml 
Hirudin TFPI 
Fig. 6. Relative fficacy ofpreincubation ofclotted grafts 
with specific inhibitors for attenuating increases in FPA 
induced after 13 minutes, when grafts were subsequently 
incubated with recalcified citrated plasma under low-flow 
conditions (1 ml/min, n = 3 for each condition). Preincu- 
bation with either hirudin or TFPI significantly attenuated 
increases inFPA compared with clotted grafts preincubated 
with PBS (*p < 0.05 by ANOVA), but no difference was 
seen between i hibitors. 
ofprothrombin by graft-associated Xa/Va or activity 
of thrombin bound to fibrin, we hypothesized that 
plasma-clotted grafts would simulate the predomi- 
nant procoagulant mechanisms encountered in clini- 
cal experiments. Our results indicate that plasma- 
clotted grafts induce marked procoagulant activity, as 
reflected by nonlinear, accelerated fibrin formation in 
recalcified plasma. Thus the increases in FPA we 
observed when grafts were incubated in recalcified 
plasma ppeared to be attributable toboth the activity 
ofthrombin bound to fibrin and to de novo thrombin 
elaboration i duced by factor Xa/Va associated with 
the plasma clot. 
Thrombus-associated factor Xa and thrombin 
activity are resistant to antithrombin III-dependent 
therapeutic agents uch as heparin. 7Recently, novel 
antithrombotic agents including those that inhibit 
thrombin directly, factor Xa, and the tissue 
factor/VIIa/Xa complex have been developed and 
offer the potential of specific inhibition of graft- 
associated procoagulants. In theory, graft-associated 
procoagulant activity could be inhibited by either 
local application of antithrombotic agents or by 
systemic administration after graft implantation. 
However, systemic administration is fimited by the 
potential for hemorrhagic side effects and the cost of 
high doses of inhibitors. Thus local application of 
antithrombotic agents to grafts may be preferable. We 
have previously shown that preincubation of whole 
blood clots with the antithrombotic agents TFPI, 
hirudin, or TAP induced sustained attenuation of 
whole blood clot-associated procoagulant activity ex 
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Table II. FPA values after 8 minutes of graft incubation with plasma* 
Controlt clotted graft O.l ~tM Hirudin 5 ~tM TAP 
Experiment (%) (% of control) (% of control) 
1 100 34 35 
2 100 42 43 
3 100 52 32 
Mean± SEM 100 43 ± 5]' 37 ± 3]' 
Reduction(%) 0 57 63 
*Results are an average of  duplicate samples. 
]'Control = grafts preincubated in PBS. 
:~p < 0.05 versus control. 
Table III. FPA values after 13 minutes ofperfusion of grafts with plasma 
Control clotted graft 5 ~tg/ml TFPI 0.1 ~tM Hirudin 
Experiment (%) (% of control) (% of control) 
1 100 49 
2 100 64 
3 100 21 36 
4 100 47 52 
Mean + SEM 100 39 + 91" 51 + 8]. 
Reduction (%) 0 61 49 
*Control = grafts preincubated in PBS. 
]'p < 0.05 versus control. 
vivo. 10 In this study we have shown that preincubation 
of plasma-clotted grafts with these agents resulted in 
marked attenuation of the procoagulant activity in- 
duced by plasma-clotted grafts in recalcified plasma 
under static and low-flow conditions (Figs. 3, 4, and 
5 and Tables I, II, and III). These data suggest that 
local application of specific inhibitors ofthrombin and 
factor Xa may be an effective strategy for inhibiting 
graft-associated procoagulant activity in vivo. 
The mechanism(s) bywhich inhibitors of throm- 
bin and factor Xa attenuated graft-associated proco- 
agulant activity are not completely defined in this 
study. Although the results of this study and our 
previous data sl° show that preincubation ofplasma 
clots with hirudin, TAP, and TFPI inhibit clot- 
associated procoagulant thrombin and Xa activity, 
respectively, we cannot be certain in this study that 
these antithrombotic agents did not bind to the graft 
directly and inhibit subsequent procoagulant activity 
when the grafts were placed in recalcified plasma. 
Indeed, inhibition of graft-associated procoagulant 
activity may be attributable tobinding of antithrom- 
boric agents to the grafts judging from the decreases 
in FPA induced by nonclotted grafts preincubated in 
inhibitors, washed, and incubated in recalcified 
plasma compared with nonclotted grafts that had not 
previously been exposed to inhibitors (data not 
shown). However, the clinical success of local appli- 
cation of antithrombotic agents to prosthetic grafts 
will likely depend not only on inhibition ofthrombus- 
associated procoagulant activity but also on the avail- 
ability of free antithrombotic agent o locally inhibit 
activation of coagulation factors recruited from cir- 
culating blood. 
The long-term clinical consequences of initial 
attenuation of graft-associated procoagulant activity 
are not known. A reduction in thrombus formation 
early after implantation may increase the rapidity of 
graft passivation, thereby increasing raft patency 
rates. Clearly, a thrombogenic luminal surface arly 
after graft implantation would be expected to de- 
crease initial graft patency rates. In addition, elabora- 
tion of thrombin and accumulation of activated 
platelets have potent mitogenic effects that promote 
intimal hyperplasia. 12Thus attenuated early graft 
thrombogenicity may influence long-term patency by 
decreasing the extent ofintimal hyperplasia, particu- 
larly at the distal anastomosis, where graft occlusion is
frequently observed. Whittemore t al. is have dem- 
onstrated that prosthetic graft thrombosis in the 
intermediate t rm is a consequence ofintimal hyper- 
plasia.lS Thus it is reasonable tospeculate hat attenu- 
ated early luminal thrombogenicity of grafts may 
favorably influence acute and long-term patency. 
Preliminary confirmation of this concept has been 
advanced by Ragosta et al.,14 who demonstrated that 
factor Xa inhibitors were effective in attenuating 
intimal hyperplasia n a rabbit femoral artery angio- 
plasty model. 
One of the limitations of this study is that the 
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procoagulant activity of grafts was assessed under 
low-flow conditions. Others have shown that pcrfu- 
sion with nonanticoagulated whole blood at arterial 
shear rates promotes more marked thrombin-inde- 
pendent platelet deposition and platelet-rich throm- 
bosis, is Thus it is possible that the attenuation of 
procoagulant activity we observed with inhibitors 
under low-flow conditions may be abolished under 
arterial flow conditions. This seems unlikely, however, 
because local antithrombin delivery has been demon- 
strated to effectively inhibit platelet-dependent 
thrombosis under arterial flow conditions.:6 We also 
did not attempt o assess the duration of attenuation 
of procoagulant activity induced by incubation with 
specific antithrombotic agents. Presumably, recruit- 
ment of platelets and procoagulants from blood 
would occur as'local inhibitory activity diminishes 
either as a result of leaching of the inhibitor from the 
graft into the bloodstream or as the inhibitor is 
covered over by newly deposited circulating proteins 
and adherent cells. On clinical evaluation, this prob- 
lem may bc addressed by frequent local application of 
antithrombotic agents with direct drug delivery de- 
vices. 
The results of this study indicate that plasma- 
clotted grafts induce procoagulant activity as a con- 
sequence of thrombin and factor Xa/Va associated 
with the plasma clot on the luminal surface of the 
graft. Local application of antithrombotic agents to 
preclotted grafts appears to markedly attenuate the 
extent o which grafts induce activation of the coagu- 
lation system when they undergo incubation or per- 
fusion with recalcified plasma. This model is analo- 
gous to the results that might be obtained by prein- 
cubation of whole blood-clotted graft with 
antithrombotic agents before implantation. Our data 
would suggest that this strategy would at least attenu- 
ate early fibrin formation and platelet accumulation 
and might potentially influence the long-term pa- 
tency of the graft. 
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